Virtus ETF Advisers’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Virtus ETF Advisers’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,609	Closed	-$161K	–	400
2021 Q3	$161K	Sell	3,609 -189	-5%	-$9.23K	0.07%	324
2021 Q2	$207K	Buy	3,798 +1,221	+47%	+$72.3K	0.09%	324
2021 Q1	$193K	Buy	2,577 +45	+2%	+$4.67K	0.08%	331
2020 Q4	$275K	Sell	2,532 -952	-27%	-$86.9K	0.11%	264
2020 Q3	$308K	Sell	3,484 -474	-12%	-$53.9K	0.16%	216
2020 Q2	$422K	Buy	+3,958	New	+$355K	0.2%	180
2018 Q4	–	Sell	-3,560	Closed	-$424K	–	395
2018 Q3	$424K	Sell	3,560 -2,612	-42%	-$303K	0.04%	152
2018 Q2	$630K	Buy	+6,172	New	+$764K	0.56%	127

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Virtus ETF Advisers's SYRS Position: Q4 2021 in Review

Virtus ETF Advisers sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 3,609 shares — an estimated $161K sold.

Virtus ETF Advisers first reported a position in SYRS in Q2 2018 and held it in 8 quarters. The position peaked at $630K in Q2 2018. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

Virtus ETF Advisers reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Virtus ETF Advisers sold 3,609 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $161K.
Virtus ETF Advisers first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
Virtus ETF Advisers's Syros Pharmaceuticals, Inc. Common Stock position peaked at $630K in Q2 2018.
90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.